• Explore /
  • Poster
  • / A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non–small cell lung cancer (NSCLC) with <em>EGFR</em> mutation.

A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutation.

Abstract Poster

Authors

null

Youngjoo Lee

National Cancer Center, Goyang, South Korea

Youngjoo Lee , Hye Ryun Kim , Min Hee Hong , Ki Hyeong Lee , Keon Uk Park , Geon Kook Lee , Hyae Young Kim , Soo-Hyun Lee , Kun Young Lim , Sung Jin Yoon , Byoung Chul Cho , Ji-Youn Han

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03126799

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9107)

DOI

10.1200/JCO.2022.40.16_suppl.9107

Abstract #

9107

Poster Bd #

93

Abstract Disclosures

Similar Posters

First Author: Li Zhang

First Author: Rosario Garcia Campelo

First Author: Julien Mazieres

First Author: Howard Jack West